Effectiveness And Cost-Effectiveness Of HPV Vaccination And HPV-Based Cervical Cancer Screening Strategies In China
Funder
National Health and Medical Research Council
Funding Amount
$420,692.00
Summary
In the absence of preventative initiatives, up to 187,000 women will develop cervical cancer in China every year. However, the disease is preventable using human papillomavirus (HPV) vaccination and primary HPV screening. Building on previous work, we will evaluate the most effective and cost-effective options for cervical cancer prevention, in order to provide an comprehensive evidence base for China’s health decision-makers.
Evaluation Of Outcomes And Cost-effectiveness Of Implementing Next Generation Human Papillomavirus (HPV) Vaccination And Associated Primary HPV-based Cervical Cancer Screening Strategies In Australia
Funder
National Health and Medical Research Council
Funding Amount
$697,071.00
Summary
This project involves using simulation modelling to predict the effect of the next generation human papillomavirus (HPV) vaccine, which will protect against infection with more strains of HPV. The investigators will use large datasets garnered from around the world to inform the assessment of the cost-effectiveness of this new vaccine in Australia and other key countries, and also to assess whether cervical screening will need to change in the future to account for the introduction of the new va ....This project involves using simulation modelling to predict the effect of the next generation human papillomavirus (HPV) vaccine, which will protect against infection with more strains of HPV. The investigators will use large datasets garnered from around the world to inform the assessment of the cost-effectiveness of this new vaccine in Australia and other key countries, and also to assess whether cervical screening will need to change in the future to account for the introduction of the new vaccine.Read moreRead less
Skin cancer affects 60% of Australians. Nicotinamide (vitamin B3) prevents many of sunlight’s damaging effects and reduces premalignant keratoses by 35% compared to placebo in sun-damaged individuals. We now need to test whether nicotinamide can prevent skin cancer. Skin cancer patients will receive nicotinamide or placebo for 12 months and new cancers will be counted in each group. Nicotinamide is safe, widely available and an exciting opportunity for cost-effective skin cancer prevention.
Cancers of the skin are the most common tumours in humans, and their diagnosis and treatment impose the largest costs on Australia’s cancer budget. While much has been learned about the roles of sunlight and skin type as risk factors for skin cancer, relatively little is known about the genes conferring risk. This study will compare the genetic profiles of over 6000 patients with skin cancer to 3000 people without skin cancer to pinpoint the genes responsible for skin cancer.
The OUTBACK Trial - The Role Of Adjuvant Chemotherapy In Locally Advanced Cervical Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,472,782.00
Summary
This international randomized phase III trial will test the value of giving additional chemotherapy treatment to women with locally advanced cervix cancer following standard chemo-radiation treatment. The aim is to improve survival rates for these women, many of whom have a 40% or greater chance of their disease relapsing after treatment. The trial has been designed in Australia, and is open in multiple countries with Australia New Zealand Gynaecological Oncology Group (ANZGOG) as the lead group ....This international randomized phase III trial will test the value of giving additional chemotherapy treatment to women with locally advanced cervix cancer following standard chemo-radiation treatment. The aim is to improve survival rates for these women, many of whom have a 40% or greater chance of their disease relapsing after treatment. The trial has been designed in Australia, and is open in multiple countries with Australia New Zealand Gynaecological Oncology Group (ANZGOG) as the lead group.Read moreRead less
Cervical Screening Participation And Outcomes For Indigenous Australian Women
Funder
National Health and Medical Research Council
Funding Amount
$601,546.00
Summary
Cervical cancer is much more common among Indigenous than other Australian women, however little is known about their cervical screening participation or outcomes. This study will use Pap Test Registers and other data sources to compare screening participation and outcomes for Indigenous and non-Indigenous women, and investigate whether cervical cancer incidence has decreased for Indigenous women in recent years, as it has done for non-Indigenous women in Australia.
Aurora A As A Novel Therapeutic Target For HPV-driven Cancers.
Funder
National Health and Medical Research Council
Funding Amount
$762,328.00
Summary
Cervical cancer is caused by a virus and current treatments have not improved for many years. We have performed a screen and identified new drug targets and here we will examine one of these using a drug that has perviously been developed for other cancers. Our preliminary data shows cervical cancer is highly sensitive to this drug and there are few side-effects. We will examine how it works and if it results in permanent protection from new cancers.
Harnessing Endogenous L1-mediated Mutagenesis To Elucidate New Candidate Genes For Liver Cancer
Funder
National Health and Medical Research Council
Funding Amount
$632,656.00
Summary
Retrotransposons are mobile genes that copy-and-paste themselves in our genome. Previously thought to represent “junk DNA”, retrotransposons are increasingly recognised to play major roles in biology. In a recent publication in Cell, we found that retrotransposons were highly active in some types of liver cancer, mutating key genes required to block tumour formation. In the current study, we will determine in greater depth how, and how often, these genes are involved in other types of liver canc ....Retrotransposons are mobile genes that copy-and-paste themselves in our genome. Previously thought to represent “junk DNA”, retrotransposons are increasingly recognised to play major roles in biology. In a recent publication in Cell, we found that retrotransposons were highly active in some types of liver cancer, mutating key genes required to block tumour formation. In the current study, we will determine in greater depth how, and how often, these genes are involved in other types of liver cancer.Read moreRead less
Randomised Controlled Trial Of HPV Self-sampling For Improving Participation In Cervical Screening: The IPAP Trial
Funder
National Health and Medical Research Council
Funding Amount
$534,461.00
Summary
Effectiveness of cervical cancer screening relies on maximising participation. Unlike a Pap test, an HPV test may be self-collected and this may overcome some of the barriers to Pap testing. Overseas trials have found higher uptake for HPV self-sampling (between 3-30%) compared with Pap test reminder letters. We will conduct the first randomised trial in Australia comparing home-based HPV self-sampling with a reminder letter, to evaluate whether this improves participation and followup.
Bridging The GAPP Between The Laboratory And Clinic To Prevent Gastric Adenocarcinoma And Proximal Polyposis Of The Stomach (GAPPS).
Funder
National Health and Medical Research Council
Funding Amount
$724,877.00
Summary
Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS) is an inherited form of gastric cancer. Affected patients develop a large number of gastric polyps and are at risk of gastric cancer in their 30s. The only effective treatment is to surgically remove the stomach. Gastrectomy is, however, associated with significant post-operative complications. We will use laboratory and mouse models of GAPPS to identify acceptable new approaches to prevent cancer in these patients.